FINANCIAL STATEMENTS (Un-Audited)

For the period from 01.07.2017 to 31.12.2017



THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,

Dhaka-1207, Bangladesh.

AMAR STOCK

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

Muhtaram Shareholder(s),
Assalamu Alaikum Wa Rahmatullah,

As per rule 13 of Securities and Exchange Rules-1987 and Bangladesh Accounting Standard (BAS) -34, we are pleased to enclose herewith the un-audited Statement of Financial Position as at 31st December 2017, the Statement of Profit or Loss and other Comprehensive Income , Statement of Cash Flows and Statement of Changes in Equity for the half-year ended 31st December, 2017 for your kind perusal.

STATEMENT OF FINANCIAL POSITION (Un-Audited)

As at 31st December, 2017

	Notes	Amount in Taka As at 31.12.2017	 As at 30.06.2017
ASSETS:			
Non-Current Assets:		**1,767,644,914**	**1,511,177,231**
Property,Plant and Equipment	02	1,163,324,054	1,116,332,498
Capital work-in-progress	02.1	187,573,672	26,614,186
Investment in Marketable Securities (AFS)	03	407,624,041	359,107,400
Investment in associate	03.01	9,123,147	9,123,147
Current Assets :		**735,107,603**	**643,644,663**
Inventories	04	318,806,588	264,194,238
Accounts Receivable		22,067,371	14,642,851
Advances, Deposits & Prepayments	05	207,644,333	167,384,398
Cash & Cash Equivalents	06	186,589,311	197,423,176
TOTAL ASSETS		**2,502,752,517**	**2,154,821,894**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		**1,253,181,805**	**1,104,963,231**
Share Capital		284,032,980	258,211,800
Net Gain on Marketable Securities (AFS)	03	333,150,555	289,485,578
Tax Holiday Reserve		4,392,110	4,392,110
Retained Earnings	07	631,606,160	552,873,744
Non-Current Liabilities	08	**383,319,367**	**242,737,392**
Deferred Tax Liability	09	**89,829,541**	**80,513,227**
Current Liabilities:		**776,421,804**	**726,608,044**
Bank & Other Finance	10	277,490,453	326,811,195
Accounts and Other Payables	11	498,931,351	399,796,849
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**2,502,752,517**	**2,154,821,894**
Net Asset Value (NAV) per Share (restated-30.06.2017)		**44.12**	**38.90**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka
27-Jan-17

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)

For the Half-year ended 31st December, 2017

	Notes	Amount in Taka			
		For the half-year (July 01, 2017 to December 31, 2017)	For the half-year (July 01, 2016 to December 31, 2016)	For the Quarter (October 01, 2017 to December 31, 2017)	For the Quarter (October 01, 2016 to December 31, 2016)
Revenue		2,469,779,682	1,978,586,249	1,234,368,494	1,045,838,834
Cost of goods sold	12	(1,467,599,537)	(1,177,512,003)	(733,784,069)	(622,203,150)
Gross Profit		**1,002,180,145**	**801,074,246**	**500,584,425**	**423,635,684**
Operating Expenses:					
Administrative expenses	13	(55,058,922)	(46,366,506)	(25,921,798)	(23,350,582)
Selling & Distribution expenses	14	(706,673,990)	(565,536,172)	(327,209,235)	(272,579,392)
		(761,732,912)	**(611,902,678)**	**(353,131,033)**	**(295,929,974)**
Operating Profit		**240,447,233**	**189,171,568**	**147,453,392**	**127,705,710**
Financial charges		(17,847,994)	(7,923,834)	(10,338,245)	**(5,827,671)**
Other income		350,798	2,036,052	300,647	1,712,682
		222,950,037	**183,283,786**	**137,415,794**	**123,590,721**
Workers' P.P. Fund & Welfare Fund		(10,616,668)	(8,727,799)	(6,543,609)	(5,885,272)
Net Profit before tax		**212,333,369**	**174,555,987**	**130,872,185**	**117,705,449**
Less: Income tax expenses					
Current tax		(47,691,474)	(36,099,747)	(28,068,927)	(22,599,495)
Deferred tax	09	4,464,651	6,700,069	4,335,739	6,914,346
		(43,226,823)	**(29,399,678)**	**(23,733,188)**	**(15,685,149)**
Net Profit after tax		**169,106,546**	**145,156,309**	**107,138,997**	**102,020,300**
Other Comprehensive Income:					
Change in fair value of Marketable Securities (AFS)	03	48,516,641	5,589,616	23,198,231	(14,251,633)
Deferred tax		(4,851,664)	(558,962)	(2,319,823)	1,425,163
Total other comprehensive income for the period, net of tax		43,664,977	5,030,654	20,878,408	(12,826,470)
Total other comprehensive income for the period 31st December, 2017		**212,771,523**	**150,186,963**	**128,017,405**	**89,193,830**
Earnings per share-basic (restated-2016)		**5.95**	**5.11**	**3.77**	**3.59**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka
27-Jan-17

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF CHANGES IN EQUITY (Un-Audited)

For the Half-year ended 31st December, 2017

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st July, 2016	**224,532,000**	**4,392,110**	**259,716,820**	**380,790,698**	**869,431,628**
Net profit after tax	-	-	29,768,758	233,829,346	263,598,104
Dividend for the year 30 June, 2016 (Cash-12.50%)			-	(28,066,500)	(28,066,500)
Dividend for the year 30 June, 2016 (Stock-5%)	33,679,800			(33,679,800)	-
Balance as at 1st July, 2017	**258,211,800**	**4,392,110**	**289,485,578**	**552,873,744**	**1,104,963,232**
Total Comprehensive Income/(Loss)			43,664,977	169,106,546	212,771,523
for the period ended 30th June, 2017 (Cash-25%)				(64,552,950)	(64,552,950)
Dividend for the year 30th June, 2017 (Stock-10%)	25,821,180			(25,821,180)	-
Balance as at 31st December, 2017	**284,032,980**	**4,392,110**	**333,150,555**	**631,606,160**	**1,253,181,805**

STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Un-Audited)

For the Half-year ended 31st December, 2016

Restated

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (Unrealized)	Retained Earnings	Total
Balance as at 1st January, 2016	**224,532,000**	**4,392,110**	**245,913,549**	**358,108,009**	**832,945,668**
Total Comprehensive Income/(Loss)-2016			13,803,271	78,815,689	92,618,960
Dividend for the year, 2015 (Cash-25%)				(56,133,000)	(56,133,000)
Balance as at 1st July, 2016	**224,532,000**	**4,392,110**	**259,716,820**	**380,790,698**	**869,431,628**
Total Comprehensive Income/(Loss)	-	-	-	-	-
for the period ended 31st December, 2016	-	-	5,030,654	145,156,309	150,186,963
Dividend for the half year, 2016 (Cash-12.50%)	-	-	-	(28,066,500)	(28,066,500)
Dividend for the 18th months, 2016 (Stock-15%)	33,679,800	-	-	(33,679,800)	-
Balance as at 31st December, 2016	**258,211,800**	**4,392,110**	**264,747,474**	**464,200,707**	**991,552,091**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka
27-Jan-17

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

STATEMENT OF CASH FLOWS (Un-Audited)

For the Half-year ended 31st December, 2017

	Amount in Taka	
	Half-year ended 31.12.2017	Half-year ended 31.12.2016
Cash Flow From Operating Activities:		
Collection from customers & others	2,462,004,364	1,969,125,677
Payment for cost & expenses	(2,207,024,385)	(1,860,196,389)
Miscellaneous Income	150,151	321,540
Cash genenated from operations	**255,130,130**	**109,250,828**
Income tax paid	(15,678,357)	(18,198,289)
Financial charges	(17,847,994)	(7,923,834)
Net cash provided by operating activities	**221,603,779**	**83,128,705**
Cash Flow From Investing Activities:		
Purchase of fixed assets	(256,138,476)	(110,352,781)
Profit from bank deposits & investment	200,647	1,714,512
Net cash used in investing activities	**(255,937,829)**	**(108,638,269)**
Cash Flow From Financing Activities:		
Payment of dividend	(44,678,178)	(85,281,550)
Long term finance received/(paid) from bank (net)	117,499,106	84,780,828
Short term finance received/(paid) from bank (net)	(49,320,743)	31,180,398
Net cash flow from financing activities	**23,500,185**	**30,679,676**
Increase/(decrease) in cash and cash equivalents	(10,833,865)	5,170,112
Cash and cash equivalents at the opening	197,423,176	169,305,904
Cash and cash equivalents at the closing	**186,589,311**	**174,476,016**
Net operating cash flow per share (NOCFPS) (restated-2016)	**7.80**	**2.93**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka
27-Jan-17

Selected Explanatory Notes

01 (a). Basis of Preparation of Financial Statements

These fianacial Statements have been prepared in line with the accounting policies and methods of computations of the annual financial statements prepared and published for the year ended 30th June, 2017. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

01 (b). Reporting

This half-yearly financial report has been prepared based on Bangladesh Accounting Standard (BAS)-34 "Interim Financial Reporting".

01 (c) Earnings Per Share (EPS)

Earnings per share has been calculated based on number of shares outstanding for the period ended December 31, 2017 and profit for the same period. The number of shares outstanding for the period was 28.403 million. Earnings per share for the corresponding period of 2016 has also been calculated based on 28.403 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01. (d) Restatement of Financial Statement:

Statement of profit or loss and other comprehensive income and statement of changes in equity for the half-year ended on 31st December 2016 has been restated for more compliance with accounting standard by recognising deferred tax on gain/(loss) of marketable securities (available for sales, AFS).

01 (e). Finance charge:

Long term loan balance was Tk.346,995,053.00 and 229,495,947.00 on 31 December 2017 and 30 June 2017 respectively. Due to increase in long term loan finance charge was increased during the reporting period.

01 (f). Net Operating cash flow per share (NOCFPS):

The increase in NOCFPS arose due to the decrease in percentage of payment for trade and other payable and advance income tax in the current reporting period.

01.(g) Subsequent events

No Material events occured after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

	Amount in Taka	
	As at 31.12.2017	As at 30.06.2017
02. PROPERTY, PLANT AND EQUIPMENT:		
Cost/Revaluation		
Opening Balance	1,606,348,997	1,352,403,379
Addition during the period	95,178,990	257,621,978
Disposal/Adjustment during the period	-	(3,676,360)
	1,701,527,987	1,606,348,996
Accumulated Depreciation		
Opening Balance	490,016,500	400,679,809
Charged during the period	48,187,433	92,504,197
Disposal/Adjustment during the period	-	(3,167,508)
	538,203,933	490,016,498
Written Down Value (WDV)	**1,163,324,054**	**1,116,332,498**
02.1 Capital work-in-progress		
Construction work-in-progress (Building)	35,197,392	26,614,186
Machinery in transit	152,376,280	-
	187,573,672	**26,614,186**

03. INVESTMENT IN MARKETABLE SECURITIES (FAIR VALUE):

Sl No.	Name of Company Share/Bond	No. of Shares /Bond Held	Face Value Per Share /Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/ Bond as on 31.12.17	Total Market value of shares/ Bond as on 31.12.17	Unrealized Gain/(Loss)
1	Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,013,991	10	32,866,758	2.98	36.60	403,112,071	370,245,313
2	Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	983.00	4,511,970	(78,030)
	Total Taka			**37,456,758**			**407,624,041**	**370,167,283**

	Amount in Taka	
	As at 31.12.2017	As at 30.06.2017
a) NET GAIN/(LOSS) ON MARKETABLE SECURITIES (AFS) :		
Unrealized Gain/(Loss) Position (Closing)	370,167,283	321,650,642
Defered tax on gain on marketable securities (AFS)	(37,016,728)	(32,165,064)
	333,150,555	**289,485,578**
b) CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES (AFS) :		
Unrealized Gain/(Loss) Position (Closing)	370,167,283	321,650,642
Unrealized Gain/(Loss) Position (Opening)	(321,650,642)	(288,574,244)
	48,516,641	**33,076,398**
03.1 INVESTMENT IN ASSOCIATE		
Opening balance	9,123,147	1,750,000
Add: Addition during the year	-	8,000,000
Less: Share of associate profit/(loss)	-	(626,853)
IBN SINA Consumer Products Ltd.	**9,123,147**	**9,123,147**
IBN SINA Consumer Products Ltd. (40% of total share holding)		
04. INVENTORIES:		
Raw materials	107,686,998	88,563,456
Packing materials	87,378,905	68,253,484
Work-in-process	52,752,125	43,928,563
Finished goods	68,415,229	61,978,640
Physicians' samples & others	2,573,331	1,470,095
	318,806,588	**264,194,238**
05. ADVANCES, DEPOSITS & PRE-PAYMENTS :		
This is recoverable in cash or for value to be received and consists of as follows :		
a. Advances against-		
Salary	2,124,248	2,104,138
Expenses/Works	5,006,154	4,964,944
Head office	7,965,000	7,965,000
Sales centre rent	8,702,625	9,036,110
Motor cycles - To employees	6,372,605	5,649,951
Income Tax	140,018,375	123,113,838
Others	337,342	247,492
	170,526,349	153,081,473
b. Deposits -		
Security money	12,694,981	12,727,278
c. Pre-payments -		
Value Added Tax (VAT)	24,320,005	1,009,106
Insurance premium	102,998	566,541
	24,423,003	1,575,647
(a+b+c)	**207,644,333**	**167,384,398**

		Amount in Taka	
		As at 31.12.2017	As at 30.06.2017
06.	**CASH & CASH EQUIVALENTS:**		
	Cash in hand & Bank Balance	180,615,311	191,833,176
	Imprest Cash	5,974,000	5,590,000
		186,589,311	**197,423,176**
07.	**RETAINED EARNINGS :**		
	Retained Earnings	552,873,744	380,790,698
	Dividend Paid	(90,374,130)	(61,746,300)
	Add : Surplus during the period/year	169,106,546	233,829,346
		631,606,160	**552,873,744**
08.	**NON-CURRENT LIABILITIES:**		
	Long Term Finance-Net off current maturity	346,995,053	229,495,947
	Retirement Benefit Obligation	36,324,314	13,241,445
		383,319,367	**242,737,392**
09.	**DEFERRED TAX ASSET/LIABILITY :**		
	Deferred Tax Asset/Liability represents deferred tax recognized as asset/liability the movement of which is as below:		
	a) Deferred tax liability on net temprorary differences:		
	Balance as at 1st January	48,348,163	39,478,199
	Deferred tax expenses/(income)	4,464,651	8,869,965
		52,812,814	**48,348,164**
	b) Deferred tax liability on change in AFS :		
	Balance as at 1st January	32,165,063	28,857,423
	Addition/(Less) during the year	4,851,664	3,307,640
		37,016,727	**32,165,063**
	Deferred tax liability at closing balance (a+b)	**89,829,541**	**80,513,227**
10.	**BANK & OTHER FINANCE :**		
	Short Term Finance	254,295,732	280,421,753
	Long Term Finance-Current maturity	23,194,721	46,389,442
		277,490,453	**326,811,195**
11.	**ACCOUNTS AND OTHER PAYABLES:**		
	Payable for Suppliers	170,011,308	141,010,095
	Accrued Expenses	97,231,582	85,580,582
	Deposits	7,396,660	7,183,446
	Other Finance	61,218,963	51,867,542
	Income Tax Liability	163,072,838	114,155,184
		498,931,351	**399,796,849**

		Amount in Taka	
		For the half-year (July 01, 2017 to December 31, 2017)	For the half-year (July 01, 2016 to December 31, 2016)
12.	**COST OF GOODS SOLD :**		
	Materials	1,187,654,996	953,665,707
	Factory Overhead	238,671,046	187,572,411
	Depreciation	41,273,495	36,273,885
		1,467,599,537	**1,177,512,003**
13.	**ADMINISTRATIVE EXPENSES :**		
	Salary, wages & Allowances	34,361,577	27,074,896
	Repairs & Maintenance	3,119,974	1,901,371
	Travelling & Conveyance	1,594,732	952,299
	AGM, Fees and Others	1,347,853	601,581
	Depreciation	2,603,491	2,564,081
	Other Expenses	12,031,295	13,272,278
		55,058,922	**46,366,506**
14.	**SELLING & DISTRIBUTION EXPENSES :**		
	Salary, wages & Allowances	417,665,451	351,610,759
	Travelling & Conveyance	2,462,843	1,829,033
	Market Survey & Research and Product development	3,919,413	2,345,415
	Field personnel expenses	97,687,199	71,426,011
	Sample, Literature & Promotional Expenses	38,867,865	26,594,148
	Delivery Expenses	71,732,199	58,210,012
	Depreciation	5,310,447	4,607,219
	Other Expenses	69,028,573	48,913,575
		706,673,990	**565,536,172**

Chief Financial Officer | Company Secretary | Director

Managing Director | Chairman

Dated, Dhaka
27-Jan-17

AMAR STOCK